16 results on '"Denys, Hannelore"'
Search Results
2. Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
- Author
-
Vakaet Vincent, MD, Van Hulle Hans, PhD, Van de Vijver Koen, Hilderson Ingeborg, Naert Eline, De Neve Wilfried, Vandorpe Jo, Hendrix An, Göker Menekse, Depypere Herman, Vergauwen Glenn, Van den Broecke Rudy, De Visschere Pieter, Braems Geert, Vandecasteele Katrien, Denys Hannelore, and Veldeman Liv
- Subjects
Breast cancer ,Neo-adjuvant radiotherapy ,Overall treatment time ,Feasibility ,Simultaneously integrated boost ,Accelerated radiotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective: Neo-adjuvant radiotherapy (NART) for breast cancer has shown promising survival results in retrospective trials. However, there are some obstacles such as a chemotherapy delay, an increased overall treatment time (OTT) and the risk of increasing surgical morbidity. Accelerated radiotherapy (RT) in 5 fractions allows to deliver NART in a very short time span and minimizes the delay of surgery and chemotherapy. This trial investigates this NART schedule for safety, feasibility and OTT. Material and methods: Twenty patients eligible for neo-adjuvant chemotherapy (NACT) and breast conserving surgery, were randomized between NART before NACT or NACT and postoperative RT. In both arms, RT treatment was given in 5 fractions to the whole breast with a simultaneously integrated boost (SIB) on the tumor(bed). Lymph node irradiation was given concomitantly in case of lymph node involvement. OTT was defined as the time from diagnosis to last surgery in the intervention group, while in the control group the time between diagnosis and last RT-fraction was used. In the intervention group NACT-delay was defined as time between diagnosis and start of chemotherapy. Results: 20 patients were included, and 19 patients completed treatment. OTT was significantly shorter in the intervention group (mean 218 days, range 196–253) compared to the control group (mean 237, range 211–268, p = 0.001). The difference in mean duration from diagnosis to the first treatment was a non-significant 4 days longer (31 vs 27 days, p = 0.28), but the start of NACT after diagnosis was delayed by 21 days (48 vs 27 days, p
- Published
- 2022
- Full Text
- View/download PDF
3. Corneal features in trastuzumab emtansine treatment: not a rare occurrence
- Author
-
Deklerck, Els, Denys, Hannelore, and Kreps, Elke O.
- Published
- 2019
- Full Text
- View/download PDF
4. Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients
- Author
-
Van Hulle, Hans, Vakaet, Vincent, Post, Giselle, Van Greveling, Annick, Monten, Chris, Hendrix, An, Van de Vijver, Koen, Van Dorpe, Jo, De Visschere, Pieter, Braems, Geert, Vandecasteele, Katrien, Denys, Hannelore, De Neve, Wilfried, and Veldeman, Liv
- Published
- 2020
- Full Text
- View/download PDF
5. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma.
- Author
-
Göker, Menekse, Deblaere, Stephanie, Denys, Hannelore, Vergauwen, Glenn, Naert, Eline, Veldeman, Liv, Monten, Chris, Van den Broecke, Rudy, Van Dorpe, Jo, Braems, Geert, and Van de Vijver, Koen
- Subjects
BREAST cancer prognosis ,BIOMARKERS ,PROGRAMMED death-ligand 1 ,LOBULAR carcinoma ,SAMPLE size (Statistics) ,EPIDERMAL growth factor receptors ,LYMPHOCYTES ,GENE expression ,DUCTAL carcinoma ,BREAST cancer ,ESTROGEN receptors ,HISTOLOGICAL techniques ,DESCRIPTIVE statistics ,BREAST tumors - Abstract
Simple Summary: The immunological profile of pleomorphic invasive lobular cancer is poorly investigated. pILC is characterized by more aggressive behavior and a worse prognosis; however, this rare subtype lacks a specific treatment approach. Here, we investigated the expression of sTILs and analyzed the PD-L1 expression levels from sixty-six patients with pILC. Moreover, we analyzed the association between sTILs and PD-L1 expression with other prognostic or predictive biomarkers and correlated sTILs and PD-L1 expression with survival outcomes. sTILS (≥1%) was present in 64% of the patients, and 36% of the tumors demonstrated a positive PD-L1 using SP142 (≥1%) and 28% had a positive PD-L1 score of ≥1 using 22C3. We found no differences between the molecular subtypes, the clinicopathological features, and the immune parameters, probably due to the small sample size of the HER2+ and TN subgroups. Larger trials on the immune composition of the subtypes of lobular breast cancer are needed. Background: The prognostic and predictive role of stromal tumor-infiltrating lymphocytes (sTILs) is undetermined in pleomorphic invasive lobular cancer (pILC). The same applies for the expression of PD-1/PD-L1 in this rare breast cancer subtype. Here, we aimed to investigate the expression of sTILs and analyze the PD-L1 expression levels in pILC. Methods: Archival tissues from sixty-six patients with pILC were collected. The sTIL density was scored as a percentage of tumor area using the following cut-offs: 0%; <5%; 5–9%; and 10–50%. The PD-L1 expression was analyzed using IHC on formalin-fixed, paraffin-embedded tissue sections using SP142 and 22C3 antibodies. Results: A total of 82% of the sixty-six patients were hormone receptor positive and 8% of cases were triple negative (TN), while 10% showed human epidermal growth factor receptor 2 (HER2) amplification. sTILs (≥1%) were present in 64% of the study population. Using the SP142 antibody, 36% of tumors demonstrated a positive PD-L1 score of ≥1%, and using the 22C3 antibody, 28% had a positive PD-L1 score of ≥1. There was no correlation between sTILs or PD-L1 expression and tumor size, tumor grade, nodal status, expression of estrogen receptor (ER), or amplification of HER2. Our data did not show any difference in survival between the three molecular subtypes of pILC with respect to sTILs and PD-L1 expression. Conclusion: This study shows that pILCs show some degree of sTILs and PD-L1 expression; however, this was not associated with a survival improvement. Additional large trials are needed to understand immune infiltration in lobular cancer, especially in the pleomorphic subtype. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
- Author
-
Kruse, Vibeke, Denys, Hannelore, Van Den Broecke, Rudy, Van Belle, Simon, and Cocquyt, Veronique
- Published
- 2013
- Full Text
- View/download PDF
7. ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
- Author
-
Agostinetto, Elisa, Nader-Marta, Guilherme, Paesmans, Marianne, Ameye, Lieveke, Veys, Isabelle, Buisseret, Laurence, Neven, Patrick, Taylor, Donatienne, Fontaine, Christel, Duhoux, Francois P, Canon, Jean-Luc, Denys, Hannelore, Coussy, Florence, Chakiba, Camille, Ribeiro, Joana Mourato, Piccart, Martine, Desmedt, Christine, Ignatiadis, Michail, and Aftimos, Philippe
- Abstract
Invasive lobular carcinoma (ILC) is the most common histologic subtype of breast cancer after invasive ductal carcinoma (i.e., no special type [NST]). ILC differs from NST in clinical presentation, site-specific metastases and response to conventional therapies. Loss of E-cadherin protein expression, due to alterations in its encoding gene CDH1, is the most frequent oncogenic event in ILC. Synthetic lethality approaches have shown promising antitumor effects of ROS1 inhibitors in models of E-cadherin-defective breast cancer in in vivo studies and provide the rationale for testing their clinical activity in patients with ILC. Entrectinib is a tyrosine kinase inhibitor targeting TRK, ROS1 and ALK tyrosine kinases. Here, the authors present ROSALINE (NCT04551495), a phase II study testing neoadjuvant entrectinib and endocrine therapy in women with estrogen receptor-positive, HER2-negative early ILC. Breast cancer is the most common cancer among women worldwide. Breast cancer is not a unique disease, but rather a heterogeneous disease, with different subtypes. Lobular breast cancer is the second most common histologic subtype of breast cancer after ductal breast cancer. Lobular breast cancer has some peculiar characteristics that make it a distinct entity in the context of breast cancer. Nevertheless, few clinical studies so far have focused specifically on this subtype. ROSALINE is a clinical study aimed to test entrectinib, a new drug that showed promising activity in preliminary research studies, in combination with endocrine therapy in women with lobular breast cancer before surgery. Trial Registration Number: NCT04551495 (ClinicalTrials.gov). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Robust sequential biophysical fractionation of blood plasma to study variations in the biomolecular landscape of systemically circulating extracellular vesicles across clinical conditions.
- Author
-
Vergauwen, Glenn, Tulkens, Joeri, Pinheiro, Cláudio, Avila Cobos, Francisco, Dedeyne, Sándor, De Scheerder, Marie‐Angélique, Vandekerckhove, Linos, Impens, Francis, Miinalainen, Ilkka, Braems, Geert, Gevaert, Kris, Mestdagh, Pieter, Vandesompele, Jo, Denys, Hannelore, De Wever, Olivier, and Hendrix, An
- Subjects
EXTRACELLULAR vesicles ,BLOOD plasma ,DENSITY gradient centrifugation ,BREAST cancer ,NON-coding RNA ,BLOOD testing - Abstract
Separating extracellular vesicles (EV) from blood plasma is challenging and complicates their biological understanding and biomarker development. In this study, we fractionate blood plasma by combining size‐exclusion chromatography (SEC) and OptiPrep density gradient centrifugation to study clinical context‐dependent and time‐dependent variations in the biomolecular landscape of systemically circulating EV. Using pooled blood plasma samples from breast cancer patients, we first demonstrate the technical repeatability of blood plasma fractionation. Using serial blood plasma samples from HIV and ovarian cancer patients (n = 10) we next show that EV carry a clinical context‐dependent and/or time‐dependent protein and small RNA composition, including miRNA and tRNA. In addition, differential analysis of blood plasma fractions provides a catalogue of putative proteins not associated with systemically circulating EV. In conclusion, the implementation of blood plasma fractionation allows to advance the biological understanding and biomarker development of systemically circulating EV. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Heterogeneous Response of Chemotherapy-Related Cognitive Decline in Patients with Breast Cancer: A Prospective Study.
- Author
-
Schrauwen, Wim, Van de Cavey, Joris, Vingerhoets, Guy, Vanheule, Stijn, Van den Broecke, Rudy, and Denys, Hannelore
- Subjects
BREAST cancer ,CANCER treatment ,CANCER patients ,OLDER patients ,LONGITUDINAL method ,PATIENT education - Abstract
Objective: A significant proportion of adjuvant-treated breast cancer patients experience cognitive decline, challenging the person's ability to return to normal activities after treatment. However, not every patient experiences cognitive problems, and even in patients with impairments, determining clinically important cognitive decline remains challenging. Our objective was to explore differences in neuropsychological performance following adjuvant chemotherapy (CT) in patients with breast cancer. Method: We conducted a prospective observational study in an Oncology Breast Clinic and assessed neuropsychological performance before and after adjuvant CT and in non-CT-treated women with breast cancer and healthy controls (HCs). Standardised between-group differences and regression-based change scores were calculated. Results: CT-treated patients (n = 66) performed significantly different from non-CT-treated patients (n = 39) and HCs (n = 56). There was a significant effect on verbal fluency (p =.0013). CT performed significantly worse than non-CT and HC [effect size (ES) =.89, p <.001 and ES =.61, p ≤.001, respectively] and from HCs with regard to proactive interference (ES =.62, p ≤.001). Regression-based scores revealed more severe cognitive decline in the CT-treated group [24.24% (16/66)] than in the non-CT-treated group [15.20% (6/39)] and HC group [7.14% (4/56)]. Patients who underwent CT and showed cognitive decline were less educated and older, with significantly lower baseline scores. Conclusions: CT-treated patients showed more vulnerability on cognitive control and monitoring than non-CT-treated breast cancer patients and HCs. Older patients with less education and lower baseline cognitive performance represent a group at risk for cognitive decline following CT. Identification of patients at risk for decline could improve targeted support and rehabilitation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Adipose tissue in breast cancer : not an idle bystander but an active participant in breast cancer progression
- Author
-
Lapeire, Lore, Hendrix, An, Lambein, Kathleen, Braems, Geert, Valet, P, Van den Broecke, Rudy, Bracke, Marc, Cocquyt, Veronique, Denys, Hannelore, and De Wever, Olivier
- Subjects
obesity ,breast cancer ,Medicine and Health Sciences ,skin and connective tissue diseases ,adipokines ,adipose tissue - Abstract
Background: Adipose tissue is a dynamic organ that secretes a plethora of molecules called adipokines. In breast cancer we find a unique situation were genetically changed cells (the cancer cells) are in close contact with adipocytes. Moreover, obesity is a known negative prognostic marker for postmenopausal breast cancer patients. We hypothesize that adipocyte-derived factors influence breast cancer progression. Materials and methods: Adipose tissue was collected from breast cancer patients undergoing a mastectomy. After macroscopic removal of blood vessels and connective tissue, the adipose tissue was carefully cut into 2-3mm3 pieces and were incubated in specific adipose-tissue culture medium. After 24h, the medium was collected and the quality was checked by determining the concentration of total proteins, leptin, adiponectin, TNFalpha and triglycerides. This conditioned medium of adipose tissue (CM AT) was used for in vitro experimentation with MCF-7 breast cancer cells. Results: Effect of AT on morphology and aggregation: when MCF-7 cells are grown in a culture flask, they tend to form round compact islands. Under influence of CM AT, the islands form sharp edges, the cells in an island can be counted individually and they show scattering. Importantly, despite the major changes in cellular morphology, CM AT removal rescued the compact island formation of MCF-7 cells. In the slow aggregation assay, cells treated with CM AT (and a subtherapeutic concentration of a neutralizing E-cadherin antibody) lost the ability to form compact aggregates. Furthermore, MCF-7 spheroids placed inside adipose tissue showed massive reorganization into an irregularly shaped mass. Effect of AT on proliferation: starting from an equal number of cells and counting them every 2 days, it became clear that MCF-7 cells with CM AT had a higher rate of proliferation than MCF-7 cells in control medium. This stimulation of proliferation was confirmed by cell cycle analysis which revealed a doubling of cells in the G2/M phase, and western blot which showed an upregulation of cyclin A and cyclin E, both positive regulators of the cell cycle. Effect of AT on invasion: a 24h collagen type I invasion assay revealed invasive characteristics of MCF-7 cells treated with CM AT while MCF-7 cells in control conditions are round and non-invasive. In contrast, a transwell collagen test over 14 days was not able to show MCF-7 cells invading the collagen gel under influence of CM AT. However, the growth pattern of MCF-7 cells on the collagen gel was clearly disorganised when compared with the control situation. Conclusion: These findings suggest that adipose tissue-derived factors exert a dramatic selective force on patterning, invasion and growth of MCF-7 breast cancer cells. Unraveling the mechanism behind these observations may provide vital information regarding the link between obesity and poor prognosis in postmenopausal breast cancer.
- Published
- 2011
11. When fat becomes an ally of the enemy: adipose tissue as collaborator in human breast cancer.
- Author
-
Lapeire, Lore, Denys, Hannelore, Cocquyt, Véronique, and De Wever, Olivier
- Subjects
- *
FAT , *ADIPOSE tissues , *BREAST cancer , *LEPTIN , *OBESITY - Abstract
Since the discovery of leptin in 1994, our vision of adipose tissue as a static organ regulating mainly lipid storage and release has been completely overthrown, and adipose tissue is now seen as an active and integral organ in human physiology. In the past years, extensive research has tremendously given us more insights in the mechanisms and pathways involved not only in normal but also in 'sick' adipose tissue, for example, in obesity and lipodystrophy. With growing evidence of a link between obesity and several types of cancer, research focusing on the interaction between adipose tissue and cancer has begun to unravel the interesting but complex multi-lateral communication between the different players. With breast cancer as one of the first cancer types where a positive correlation between obesity and breast cancer incidence and prognosis in post-menopausal women was found, we have focused this review on the paracrine and endocrine role of adipose tissue in breast cancer initiation and progression. As important inter-species differences in adipose tissue occur, we mainly selected human adipose tissue and breast cancer-based studies with a short reflection on therapeutic possibilities. This review is part of the special issue on "Adiposopathy in Cancer and (Cardio)Metabolic Diseases". [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
- Author
-
Bockstal, Mieke, Lambein, Kathleen, Gevaert, Olivier, Wever, Olivier, Praet, Marleen, Cocquyt, Veronique, Broecke, Rudy, Braems, Geert, Denys, Hannelore, and Libbrecht, Louis
- Subjects
DUCTAL carcinoma ,BREAST cancer ,ADENOCARCINOMA ,RADIOSCOPIC diagnosis ,MAMMOGRAMS - Abstract
Aims The incidence of ductal carcinoma in situ ( DCIS) has increased since the introduction of screening mammography. Recurrence prediction is still not accurate, and could be improved by identifying additional prognostic markers. Periductal stroma actively participates in early breast cancer progression. Therefore, the aim of this study was to explore the prognostic potential of stromal characteristics in DCIS. Methods and results Histopathological features and hormone receptor/ HER2 status were analysed in a first cohort of 65 cases of DCIS with a median follow-up of 112 months. Cox regression analysis revealed that myxoid stromal architecture was significantly associated with increased ipsilateral locoregional recurrence ( P = 0.015). Next, we performed immunohistochemical screening of nine stromal proteins in a second cohort of 82 DCIS cases, and correlated their expression with stromal architecture. Because reduced stromal decorin expression correlated most strongly with myxoid stroma ( P < 0.001), it was selected for further analysis in the first cohort. Patients with reduced periductal decorin expression had a higher risk of recurrence ( P = 0.008). Furthermore, HER2 overexpression was significantly associated with invasive but not with in situ recurrence ( P = 0.007). Conclusions Periductal myxoid stroma and reduced periductal decorin expression seem to be prognostic for overall ipsilateral locoregional recurrence in DCIS, whereas HER2 expression might be a more specific biomarker for invasive recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer.
- Author
-
Lambein, Kathleen, Van Bockstal, Mieke, Vandemaele, Lies, Geenen, Sofie, Rottiers, Isabelle, Nuyts, Ann, Matthys, Bart, Praet, Marleen, Denys, Hannelore, and Libbrecht, Louis
- Subjects
HER2 gene ,PROTO-oncogenes ,IMMUNOHISTOCHEMISTRY ,HISTOCHEMISTRY ,BREAST cancer - Abstract
Objectives: To investigate the clinical and pathobiological significance of distinguishing score 0 and score 1+ within the group of immunohistochemistry (IHC)-negative invasive breast cancers. Methods: We studied HER2 status using both IHC and fluorescence in situ hybridization (FISH) in 150 consecutive breast tumors submitted to our laboratory after a negative IHC result in local testing centers. Results: We were able to discern a group of score 0 tumors that had a lower HER2 copy number than the group consisting of score 1+ tumors. In contrast with the group of score 1+ tumors, HER2 FISH was consistently negative for both copy number-based and ratio-based tumors without equivocal results. Conclusions: In a setting with stringent quality assurance, score 0 and score 1+ tumors emerge as distinct and clinically important subgroups within the HER2 IHC-negative population. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. Effect of the Secretory Small GTPase Rab27B on Breast Cancer Growth, Invasion, and Metastasis.
- Author
-
Hendrix, An, Maynard, Dawn, Pauwels, Patrick, Braems, Geert, Denys, Hannelore, Broecke, Rudy Van den, Lambert, Jo, Belle, Simon Van, Cocquyt, Veronique, Gespach, Christian, Bracke, Marc, Seabra, Miguel C., Gahl, William A., De Wever, Olivier, and Westbroek, Wendy
- Subjects
GUANOSINE triphosphatase ,TUMOR suppressor proteins ,EXOCYTOSIS ,BREAST cancer ,CANCER cell growth regulation ,GROWTH regulators - Abstract
Background: Secretory GTPases like Rab27B control vesicle exocytosis and deliver critical proinvasive growth regulators into the tumor microenvironment. The expression and role of Rab27B in breast cancer were unknown. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
15. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
- Author
-
Francesco Schettini, Sergio Venturini, Mario Giuliano, Matteo Lambertini, David J. Pinato, Concetta Elisa Onesti, Pietro De Placido, Nadia Harbeck, Diana Lüftner, Hannelore Denys, Peter Van Dam, Grazia Arpino, Khalil Zaman, Giorgio Mustacchi, Joseph Gligorov, Ahmad Awada, Mario Campone, Hans Wildiers, Alessandra Gennari, Vivianne Tjan-Heijnen, Rupert Bartsch, Javier Cortes, Ida Paris, Miguel Martín, Sabino De Placido, Lucia Del Mastro, Guy Jerusalem, Giuseppe Curigliano, Aleix Prat, Daniele Generali, Institut Català de la Salut, [Schettini F] Translational Genomics and Targeted Therapies in Solid Tumors, Barcelona, Spain. Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. Department of Medicine, University of Barcelona, Barcelona, Spain. [Venturini S] Department of Economic and Social Sciences, Catholic University of Sacred Heart - Cremona Campus, Cremona, Italy. [Giuliano M] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. [Lambertini M] Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Pinato DJ] Division of Cancer, Department of Surgery and Cancer, Imperial College London, SW7 2AZ London, UK. Department of Translational Medicine, Università del Piemonte Orientale 'A. Avogadro', Novara, Italy. [Onesti CE] Clinical and Oncological Research Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Cortes J] International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, Schettini, Francesco, Venturini, Sergio, Giuliano, Mario, Lambertini, Matteo, Pinato, David J, Onesti, Concetta Elisa, De Placido, Pietro, Harbeck, Nadia, Lüftner, Diana, Denys, Hannelore, Van Dam, Peter, Arpino, Grazia, Zaman, Khalil, Mustacchi, Giorgio, Gligorov, Joseph, Awada, Ahmad, Campone, Mario, Wildiers, Han, Gennari, Alessandra, Tjan-Heijnen, Vivianne, Bartsch, Rupert, Cortes, Javier, Paris, Ida, Martín, Miguel, De Placido, Sabino, Del Mastro, Lucia, Jerusalem, Guy, Curigliano, Giuseppe, Prat, Aleix, and Generali, Daniele
- Subjects
PD-L1 ,Paclitaxel ,Network Meta-Analysis ,BRCA ,Immunoteràpia ,Medicaments antineoplàstics - Ús terapèutic ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Algorismes ,Triple Negative Breast Neoplasms ,Immunotheraphy ,Poly(ADP-ribose) Polymerase Inhibitors ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,B7-H1 Antigen ,Sacituzumab govitecan ,Càncer de mama ,Metastasis ,Breast cancer ,Metàstasi ,Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Antineoplastic Combined Chemotherapy Protocols ,Medicine and Health Sciences ,Humans ,Radiology, Nuclear Medicine and imaging ,Trastuzumab deruxtecan ,Triple negative breast cancer ,PARP inhibitors ,Bayesian network meta-analysi ,terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Enzyme inhibitors ,Bayes Theorem ,General Medicine ,neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos [ENFERMEDADES] ,Bayesian statistical decision ,Bevacizumab ,PARP inhibitor ,Estadística bayesiana ,Inhibidors enzimàtics ,Oncology ,Settore SECS-S/01 - STATISTICA ,Mama - Càncer - Tractament ,Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms [DISEASES] ,Bayesian network meta-analysis ,Therapeutic algorithm ,Human medicine ,HER2-low ,Immunotherapy ,Pembrolizumab ,Algorithms - Abstract
Immunotherapy; PARP inhibitors; Pembrolizumab Immunoteràpia; Inhibidors de PARP; Pembrolizumab Inmunoterapia; Inhibidores de PARP; Pembrolizumab Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rates (ORR), overall survival (OS) and safety, for first and further lines, separately. We also estimated separate treatment rankings for the first and subsequent lines according to each endpoint, based on (surface under the cumulative ranking curve) SUCRA values. No first-line treatment was associated with superior PFS and OS than paclitaxel ± bevacizumab. Platinum-based polychemotherapies were generally superior in terms of ORR, at the cost of higher toxicity.. PARP-inhibitors in germline-BRCA1/2-mutant patients, and immunotherapy + chemotherapy in PD-L1-positive mTNBC, performed similar to paclitaxel ± bevacizumab. In PD-L1-positive mTNBC, pembrolizumab + chemotherapy was better than atezolizumab + nab-paclitaxel in terms of OS according to SUCRA values. In second/further-lines, sacituzumab govitecan outperformed all other treatments on all endpoints, followed by PARP-inhibitors in germline-BRCA1/2-mutant tumors. Trastuzumab deruxtecan in HER2-low mTNBC performed similarly and was the best advanced-line treatment in terms of PFS and OS after sacituzumab govitecan, according to SUCRA values. Moreover, comparisons with sacituzumab govitecan, talazoparib and olaparib were not statistically significant. The most effective alternatives or candidates for subsequent lines were represented by nab-paclitaxel (in ORR), capecitabine (in PFS) and eribulin (in PFS and OS).
- Published
- 2022
16. A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients
- Author
-
Wildiers, Hans, Jurcut, Ruxandra, Ganame, Javier, Herbots, Lieven, Neven, Patrick, De Backer, Julie, Denys, Hannelore, Cocquyt, Veronique, Rademakers, Frank, Voigt, Jens-Uwe, and Paridaens, Robert
- Subjects
- *
CANCER patients , *DOXORUBICIN , *BREAST cancer , *DRUG therapy - Abstract
Abstract: In this pilot study, we examined the feasibility and toxicity in 16 elderly women age ≥65 receiving six cycles of pegylated liposomal doxorubicin (PL-DOX) cyclophosphamide as adjuvant chemotherapy for breast cancer. An extensive cardiologic assessment was also performed including echocardiographic Doppler-based strain rate imaging (SRI), a promising new sensitive technique to assess cardiac function. All but one patient finished the six planned cycles without major dose reductions or delay, and with limited serious toxicity showing the feasibility of this regimen. Significant decreases in radial strain and strain rate were found after six cycles of treatment while left ventricle ejection fraction remained unchanged. SRI may be a useful tool in the follow-up of elderly patients treated with anthracyclines, allowing early initiation of preventive measures in order to prevent further irreversible cardiac damage. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.